Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia
Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia, Published online: 21 June 2018; doi:10.1038/s41571-018-0053-8Rituximab and ibrutinib synergize in Waldenström macroglobulinaemia (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 21, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research
Ivosidenib effective in IDH1-mutant AML
Ivosidenib effective in <i>IDH1</i>-mutant AML, Published online: 20 June 2018; doi:10.1038/s41571-018-0057-4Ivosidenib effective in IDH1-mutant AML (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 20, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Avoiding overuse of adjuvant therapies
Avoiding overuse of adjuvant therapies, Published online: 19 June 2018; doi:10.1038/s41571-018-0054-7Avoiding overuse of adjuvant therapies (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 19, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Cemiplimab effective in cutaneous SCC
Cemiplimab effective in cutaneous SCC, Published online: 19 June 2018; doi:10.1038/s41571-018-0056-5Cemiplimab effective in cutaneous SCC (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 19, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
To all involved — we have a problem
To all involved — we have a problem, Published online: 07 June 2018; doi:10.1038/s41571-018-0052-9To all involved — we have a problem (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 7, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Immunoscore provides a more accurate prognosis
Immunoscore provides a more accurate prognosis, Published online: 05 June 2018; doi:10.1038/s41571-018-0050-yImmunoscore provides a more accurate prognosis (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 5, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Safety of combining radiotherapy with immune-checkpoint inhibition
Safety of combining radiotherapy with immune-checkpoint inhibition, Published online: 05 June 2018; doi:10.1038/s41571-018-0046-7The combination of radiotherapy and immune-checkpoint inhibition (ICI) has generated considerable excitement among oncologists, and numerous clinical trials are currently exploring the efficacy of this approach; however, the safety and tolerability of this combination remains incompletely understood. In this Review, the authors describe the available data on safety considerations in patients receiving radiotherapy in combination with ICI. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 5, 2018 Category: Cancer & Oncology Authors: William L. Hwang Luke R. G. Pike Trevor J. Royce Brandon A. Mahal Jay S. Loeffler Source Type: research
Expanding ribociclib use
Expanding ribociclib use, Published online: 05 June 2018; doi:10.1038/s41571-018-0051-xExpanding ribociclib use (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 5, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Locoregional versus systemic therapy — robust positive data remain elusive
Locoregional versus systemic therapy — robust positive data remain elusive, Published online: 01 June 2018; doi:10.1038/s41571-018-0047-6Developments in the treatment of advanced-stage hepatocellular carcinoma include novel locoregional interventions aiming to induce tumour necrosis and systemic treatments targeting the biological mechanisms of tumour progression, thus aiming to delay progression. These approaches fiercely battle to provide the best survival, but their lack of success to date suggests that they might be better tested as a complementary approach. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - June 1, 2018 Category: Cancer & Oncology Authors: Marco Sanduzzi-Zamparelli Jordi Bruix Source Type: research
Steps towards effective gynaecological cancer screening
Steps towards effective gynaecological cancer screening, Published online: 31 May 2018; doi:10.1038/s41571-018-0049-4PapSEEK, a novel liquid-based cytology test, enabled the highly specific detection of endometrial and ovarian cancer in a retrospective study. Herein, I discuss potential applications of this tool, both for cancer screening of asymptomatic populations and for the early diagnosis of cancer in symptomatic women. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 31, 2018 Category: Cancer & Oncology Authors: Usha Menon Source Type: research
The new era of adjuvant therapies for melanoma
The new era of adjuvant therapies for melanoma, Published online: 30 May 2018; doi:10.1038/s41571-018-0048-5New treatment options for patients with resected stage III melanoma have been established with the publication of the results of four pivotal randomized clinical trials, resulting in three drug approvals, with a forth expected, all within only 4 years. Herein, we put these advances into context. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 30, 2018 Category: Cancer & Oncology Authors: Alexander M. M. Eggermont Caroline Robert Antoni Ribas Source Type: research
New evidence for treatment of ALAL
New evidence for treatment of ALAL, Published online: 23 May 2018; doi:10.1038/s41571-018-0045-8New evidence for treatment of ALAL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 23, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Next-generation sequencing for measuring minimal residual disease in AML
Next-generation sequencing for measuring minimal residual disease in AML, Published online: 23 May 2018; doi:10.1038/s41571-018-0040-0The prognostic significance of residual disease, measured by flow cytometry or PCR-based assays, has been established in patients with acute myeloid leukaemia (AML). The results of a recent study involving almost 500 patients in morphological remission demonstrate that detection of persistent mutations using next-generation sequencing provides information complementary to that obtained using the established methods and offer insights into AML evolution. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 23, 2018 Category: Cancer & Oncology Authors: Roland B. Walter Frederick R. Appelbaum Source Type: research
Extracellular vesicles in cancer — implications for future improvements in cancer care
Extracellular vesicles in cancer — implications for future improvements in cancer care, Published online: 23 May 2018; doi:10.1038/s41571-018-0036-9Emerging evidence indicates that tumour-derived extracellular vesicles (EVs), notably exosomes, mediate intercellular communication to promote cancer development and progression. Herein, the authors discuss EV properties and physiological functions, particularly their pro-metastatic effects, and highlight the diagnostic and therapeutic potential of EVs in cancer. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 23, 2018 Category: Cancer & Oncology Authors: Rong Xu Alin Rai Maoshan Chen Wittaya Suwakulsiri David W. Greening Richard J. Simpson Source Type: research
Novel molecular classifications of DLBCL
Novel molecular classifications of DLBCL, Published online: 22 May 2018; doi:10.1038/s41571-018-0041-zRecent genomic and transcriptomic analyses of diffuse large B cell lymphoma (DLBCL) have provided important new insights into the heterogeneous biology of this disease. The findings provide opportunities to improve treatment strategies, although considerable work is needed to establish and optimize the clinical applicability and utility of molecular classifications of DLBCL. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 22, 2018 Category: Cancer & Oncology Authors: Sydney Dubois Fabrice Jardin Source Type: research
